Market Research Logo

Generics in Australia

Generics in Australia

Summary

Generics in Australia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Australia generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

  • For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The Australian generics market had total revenues of $1.3bn in 2017, representing a compound annual growth rate (CAGR) of 0.9% between 2013 and 2017.
  • Market consumption volume increased with a CAGR of 5.5% between 2013 and 2017, to reach a total of 58% in 2017.
  • The subsidized cost of prescription medication through Australia's Pharmaceutical Benefits Scheme (PBS) for eligible patients has helped drive growth in the market share by making these products more widely available.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Australia
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Australia
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Australia generics market with five year forecasts by both value and volume
Reasons to buy
  • What was the size of the Australia generics market by value in 2017?
  • What will be the size of the Australia generics market in 2022?
  • What factors are affecting the strength of competition in the Australia generics market?
  • How has the market performed over the last five years?
  • How large is Australia’s generics market in relation to its regional counterparts?


Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Apotex, Inc.
Aspen Pharmacare Holdings Ltd
Mylan N.V.
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Appendix
About MarketLine
List of Tables
Table 1: Australia generics market value: $ million, 2013-17
Table 2: Australia generics market volume: % of total pharma, 2013-17
Table 3: Australia generics market geography segmentation: $ million, 2017
Table 4: Australia generics market value forecast: $ million, 2017-22
Table 5: Australia generics market volume forecast: % of total pharma, 2017-22
Table 6: Apotex, Inc.: key facts
Table 7: Aspen Pharmacare Holdings Ltd: key facts
Table 8: Aspen Pharmacare Holdings Ltd: key financials ($)
Table 9: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
Table 10: Aspen Pharmacare Holdings Ltd: key financial ratios
Table 11: Mylan N.V.: key facts
Table 12: Mylan N.V.: key financials ($)
Table 13: Mylan N.V.: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios
Table 17: Australia size of population (million), 2013-17
Table 18: Australia gdp (constant 2005 prices, $ billion), 2013-17
Table 19: Australia gdp (current prices, $ billion), 2013-17
Table 20: Australia inflation, 2013-17
Table 21: Australia consumer price index (absolute), 2013-17
Table 22: Australia exchange rate, 2013-17
List of Figures
Figure 1: Australia generics market value: $ million, 2013-17
Figure 2: Australia generics market volume: % of total pharma, 2013-17
Figure 3: Australia generics market geography segmentation: % share, by value, 2017
Figure 4: Australia generics market value forecast: $ million, 2017-22
Figure 5: Australia generics market volume forecast: % of total pharma, 2017-22
Figure 6: Forces driving competition in the generics market in Australia, 2017
Figure 7: Drivers of buyer power in the generics market in Australia, 2017
Figure 8: Drivers of supplier power in the generics market in Australia, 2017
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Australia, 2017
Figure 10: Factors influencing the threat of substitutes in the generics market in Australia, 2017
Figure 11: Drivers of degree of rivalry in the generics market in Australia, 2017
Figure 12: Aspen Pharmacare Holdings Ltd: revenues & profitability
Figure 13: Aspen Pharmacare Holdings Ltd: assets & liabilities
Figure 14: Mylan N.V.: revenues & profitability
Figure 15: Mylan N.V.: assets & liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report